Futibatinib for <i>FGFR2</i> -Rearranged Intrahepatic Cholangiocarcinoma

DOI Web Site 参考文献40件
  • Lipika Goyal
    From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...
  • Funda Meric-Bernstam
    From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...
  • Antoine Hollebecque
    From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...
  • Juan W. Valle
    From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...
  • Chigusa Morizane
    From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...
  • Thomas B. Karasic
    From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...
  • Thomas A. Abrams
    From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...
  • Junji Furuse
    From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...
  • Robin K. Kelley
    From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...
  • Philippe A. Cassier
    From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...
  • Heinz-Josef Klümpen
    From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...
  • Heung-Moon Chang
    From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...
  • Li-Tzong Chen
    From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...
  • Josep Tabernero
    From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...
  • Do-Youn Oh
    From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...
  • Amit Mahipal
    From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...
  • Markus Moehler
    From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...
  • Edith P. Mitchell
    From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...
  • Yoshito Komatsu
    From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...
  • Kunihiro Masuda
    From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...
  • Daniel Ahn
    From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...
  • Robert S. Epstein
    From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...
  • Abdel-Baset Halim
    From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...
  • Yao Fu
    From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...
  • Tehseen Salimi
    From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...
  • Volker Wacheck
    From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...
  • Yaohua He
    From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...
  • Mei Liu
    From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...
  • Karim A. Benhadji
    From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...
  • John A. Bridgewater
    From the Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto (L.G.), and the University of California, San Francisco, San Francisco (R.K.K.) — both in California; the Mass General Cancer Center, Harvard Medical School (L.G.), and Dana–Farber Cancer Institute (T.A.A.) — both in Boston; the University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B.); the Drug Development Department, Gustave Roussy, Villejuif (A.H.), and Centre Léon Bérard,...

収録刊行物

参考文献 (40)*注記

もっと見る

関連プロジェクト

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ